<DOC>
	<DOCNO>NCT01896284</DOCNO>
	<brief_summary>Patients neovascular age-related macular degeneration respond usual treatment conventional medication may respond new drug class design block large fraction proangiogenic factor .</brief_summary>
	<brief_title>Study Evaluate Efficacy Aflibercept Neovascular Age-related Macular Degeneration Patients Non Responders Anti-Vascular Endothelial Growth Factor</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Signed Informed Consent Men woman â‰¥ 50 year age . Any choroidal neovascular membrane ( CNVM ) lesion ( occult , minimally classic classic ) secondary agerelated macular degeneration Early Treatment Diabetic Retinopathy Study ( ETDRS ) bestcorrected visual acuity : 20/32 20/320 ( letter score 73 25 ) study eye . Able return ALL clinic visit complete studyrelated procedure . Absence ocular disease could affect visual acuity . Patients without optimal response ranibizumab bevacizumab define : Patient significant persistent recurrent fluid ( intraretinal subretinal ) OCT leakage fluorescein angiography despite least 4 injection within last 6 month , last OCT presence fluid within 6 week last treatment ranibizumab bevacizumab . Patient significant persistent recurrent fluid ( intraretinal subretinal ) OCT leakage fluorescein angiography despite three monthly treatment ranibizumab bevacizumab . No scar , fibrosis , atrophy involve center fovea No retina pigment epithelium ( RPE ) rip/tear involve central fovea Participation another simultaneous interventional clinical trial Prior treatment antiVEGF steroid therapy study eye within 28 day baseline Prior treatment photodynamic therapy ( PDT ) Intraocular surgery ( include cataract surgery ) study eye within 2 month precede Baseline History vitrectomy surgery , submacular surgery , surgical intervention AMD study eye Active intraocular inflammation study eye History cerebral vascular accident , myocardial infarction , transient ischemic attack within 3 month study enrollment . Unable undergo fluorescein angiography fundus photography uncontrolled allergy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>